chr2-47476366-G-T

Variant names:

• chr2-47476366-G-T
• rs267607988
• NM_000251.3:c.2006-1G>T

Variant summary

Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PVS1 PM2 PP5

The NM_000251.3(MSH2):​c.2006-1G>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

• Frequency: Genomes: not found (cov: 32)
• Consequence: MSH2 NM_000251.3 splice_acceptor, intron
• Scores: Splicing: ADA: 1.000
• Clinical Significance: Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:4 U:1
• Conservation: PhyloP100: 9.60
• Publications: 2 publications found

Genes affected

MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

MSH2 Gene-Disease associations (from GenCC):

• Lynch syndrome

  Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
• Lynch syndrome 1

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
• Muir-Torre syndrome

  Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
• mismatch repair cancer syndrome 1

  Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
• mismatch repair cancer syndrome 2

  Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
• ovarian cancer

  Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
• malignant pancreatic neoplasm

  Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
• prostate cancer

  Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
• rhabdomyosarcoma

  Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
• breast cancer

  Inheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
• hereditary breast carcinoma

  Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

ACMG classification

Our verdict: Pathogenic. The variant received 11 ACMG points.

• PVS1: Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
• PM2: Very rare variant in population databases, with high coverage
• PP5: Variant 2-47476366-G-T is Pathogenic according to our data. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569. Variant chr2-47476366-G-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 619569.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
MSH2	NM_000251.3	c.2006-1G>T		splice_acceptor_variant, intron_variant	Intron 12 of 15	ENST00000233146.7	NP_000242.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
MSH2	ENST00000233146.7	c.2006-1G>T		splice_acceptor_variant, intron_variant	Intron 12 of 15	1	NM_000251.3	ENSP00000233146.2

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome Cov.: 32

GnomAD4 genome Cov.: 32

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Pathogenic:4 Uncertain:1

Revision: criteria provided, conflicting classifications

Submissions by phenotype

Hereditary cancer-predisposing syndrome Pathogenic:2

Nov 22, 2021

Ambry Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The c.2006-1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide upstream from coding exon 13 of the MSH2 gene. Another alteration impacting the same acceptor site (c.2006-1G>C) has been detected in multiple patients satisfying Amsterdam Criteria I (ACI) with tumors lacking MSH2 expression on IHC (Stormorken AT, J. Clin. Oncol. 2005 Jul; 23(21):4705-12; Sjursen W, J. Med. Genet. 2010 Sep; 47(9):579-85). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -

May 29, 2020

Color Diagnostics, LLC DBA Color Health

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant causes a G to T nucleotide substitution at the -1 position of intron 12 of the MSH2 gene. Splice site prediction tools suggest that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. To our knowledge, this variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. -

Lynch syndrome 1 Pathogenic:1

Aug 07, 2023

Myriad Genetics, Inc.

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -

not provided Pathogenic:1

Mar 04, 2025

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Lynch syndrome Uncertain:1

May 01, 2018

University of Washington Department of Laboratory Medicine, University of Washington

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

MSH2 NM_000251.2:c.2006-1G>T has a 86.7% probability of pathogenicity based on combining prior probability from public data with a likelihood ratio of 0.20 to 1, generated from evidence of seeing this as a somatic mutation in a tumor without loss of heterozygosity at the MSH2 locus. See Shirts et al 2018, PMID 29887214. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_addAF	Pathogenic	0.63	D
BayesDel_noAF	Pathogenic	0.37
CADD	Pathogenic	33
DANN	Uncertain	1.0
Eigen	Pathogenic	1.3
Eigen_PC	Pathogenic	1.1
FATHMM_MKL	Pathogenic	1.0	D
PhyloP100		9.6
GERP RS		5.5
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.7
Mutation Taster		=0/100	disease causing (ClinVar)

Splicing

Name	Calibrated prediction	Score	Prediction
dbscSNV1_ADA	Pathogenic	1.0
dbscSNV1_RF	Pathogenic	0.93
SpliceAI score (max)		0.99		Details are displayed if max score is > 0.2
DS_AL_spliceai		0.99		Position offset: 1

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs267607988; hg19: chr2-47703505;